Astrazeneca stock: buy or sell

AZN stock price: $56.81 -1.13% At close on Jul 28th, 2021

Updated on:
Jul 29th, 2021


Astrazeneca stock brief

  • Astrazeneca closed on Wednesday at $56.81 (-1.13%) prior to reporting earnings on Thursday
  • Astrazeneca posted its financial report on Thursday
  • The stock is configuring an uptrend pattern since last March, when it bottomed at $46.48. This rally marked a 22.22% gain

Should I buy Astrazeneca stock?

All successful traders recommend adhering to a trading strategy and not make decisions based on subjective opinions, rumors or feelings. Trading strategies are meant for helping you in the decision process of what stocks to pick and when is the best moment to buy them. At, we like to use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best

Is $AZN stock a buy?

In the current situation of Astrazeneca there is not any eligible buy setup. This doesn't mean $AZN will slide in coming sessions, or it will not rise higher. Simply, it doesn't match our recommended trading systems

Should I sell Astrazeneca stock?

When you own stock shares with some profit, it's really hard to decide the good moment to sell and get your benefits. Trading strategies let us to avoid impulsive decisions based on our personal moods or the noise that surrounds the market. We like very simple setups to guide us on when is the best time to sell a stock. Be aware that these setups should not be used for shorting Astrazeneca stock

As a golden rule, you should never mantain an operation that leads to higher than expected losses upon the buy. When to sell shares should always be dictated by the stop-loss (automatic or manual)

Is it time to sell Astrazeneca stock?

Currently, Astrazeneca stock doesn't match any of our preferred sell setups, so if you hold Astrazeneca stock and your operation is in profit probably is not time to sell now

Astrazeneca ratings

We don't have any rating published in the last 30 days for Astrazeneca

Astrazeneca stock analysis

Astrazeneca shares started an uptrend last March, and grew an amazing 22.22%. During this uptrend, the price provided some buy points on the breakouts. Latest low was in early June, when price bounced at $55.73. Now, the price swings in a consolidation between its last top ($60.93) and its last bottom ($55.73)

SMAs overview

AZN stock SMAs chart

Supports and resistances

The current resistance levels are:

  • R1: $56.83 (0.04% above)
  • R2: $56.98 (0.30% above)
  • R3: $57.73 (1.62% above)
  • The current supports are:

  • S1: $55.90 (-1.60% below)
  • S2: $55.73 (-1.90% below)
  • S3: $55.72 (-1.92% below)
  • Bollinger bands

    Since the price broke down the lower band on July 19, the price has bounced up by 1.45%. The price is moving near to the lower Bollinger band, poiting some level of oversold in recent sessions. This is not a bullish indicator, as price can trade in these levels for many days and weeks

    AZN stock Bollinger Bands chart

    Relative strength index

    The RSI dropped below the overbought level of 70 on July 6 after just crossing to the overbough zone for a single day (weak signal). The RSI value on Wednesday was 41.93. Astrazeneca shares sank a 6.55% since then

    AZN stock RSI chart

    Astrazeneca stock price history

    Astrazeneca went public priced at an adjusted price1 of $1.95 on May 1993. Since then, AZN stock has risen by 2,813.33%, with an average of 100.48% per year. An investment of $1,000USD on the IPO would worth $29,133.33 today.

    1: Adjusted price after possible price splits or reverse-splits

    AZN stock price history chart

    Price target for Astrazeneca stock

    Nobody knows how much a stock will be priced in the future. Banks and financial organisations post their analysis predicting how a particular stock will performance in the future.

    The following table shows the price forecasts published by financial institutions over the last 30 days. If you are a small investor you don't have to trade based on these forecasts.

    We don't have any target price published in the last 4 weeks for Astrazeneca.

    Earnings and financials

    On Thursday, Astrazeneca ($AZN) had the investors event and posted the report.

    Same quarter one year ago, reported EPS was $0.48, so current EPS means -100.00%. Revenue exploded a 15.20% on an annualized basis in the , from $63.5B to $73.2B last quarter.

    Astrazeneca ($AZN) will host the quarterly earnings call.

    Stocks presenting earnings often experience a much higher volatility in its price action during after-hours trading and the day after. This extended trading range in price may imply that your stop-loss orders may become ineffective or may trigger far from your aimed price. You can probably obtain more details about the earnings call and the earnings reports on the Investor Relations section of its website:

    Astrazeneca performance

    AZN performance compared
    Astrazeneca ($AZN) -5.50% 8.70% 11.10%

    The viewpoints contained in this article are personal and should not be followed as recommendations for you to buy or sell shares. The author of this report does not have an understanding of the specific circumstances of the reader, his or her own finances or what is in his or her best interest at any given time. All users should speak with their financial advisor before buying or selling any securities Thoughts are published for general educational reasons only

    Astrazeneca summary

    Wednesday, July 28th, 2021
    Day range$56.81 - $57.43
    Previous close$57.46
    Session gain-1.13%
    Average true range$1.54
    50d mov avg$58.09
    100d mov avg$54.59
    200d mov avg$52.75
    Earnings dateDecember 31st, 1969

    Frequently asked questions

    What is Astrazeneca stock symbol?

    AstraZeneca PLC is a public company trading in the US stock market with the AZN symbol

    Is Astrazeneca stock a buy or sell?

    Astrazeneca had no ratings in the last four weeks Read the article to get additional tips on trading AZN stock.

    Will AZN go up?

    There were no price targets published by analysts in the last month for Astrazeneca.